Cedric O’Gorman - Concepedia

Author

Cedric O’Gorman

Also Known As

Bowie, Christopher R., C O'Gorman, C O’Gorman, C. O'Gorman, C. O'gorman, C. Sheila O'Gorman, Cedric O'Gorman, Cedric OʼGorman, Cedric O’Gorman

Publications

960

Citations

H-Index

Concepts

All Affiliations

Pfizer (United States)University of Miami University of North Carolina at Chapel Hill Zucker Hillside Hospital Intra Cellular Therapies (United States)

About

Cedric O’Gorman is an author at Pfizer (United States) specializing in medicine, psychiatry, and schizophrenia.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	302
2	Psychiatry	5	5	302
3	Social Sciences	3	3	257
4	Psychology	2	2	213
5	Nursing	1	1	21

Cedric O’Gorman

Publications

813

Citations

H-Index

Page 1

	Year	Citations
Efficacy and Safety of Lumateperone for Treatment of Schizophrenia Christoph U. Correll, Robert E. Davis, Michal Weingart, JAMA Psychiatry	2020	276
Determinants of different aspects of everyday outcome in schizophrenia: The roles of negative symptoms, cognition, and functional capacity Martin Strassnig, Tenko Raykov, Cedric O’Gorman, Schizophrenia Research PsychiatryRisk PredictionPsychotic DisorderPsychologySchizophrenia	2015	171
Findings of a U.S. National Cardiometabolic Screening Program Among 10,084 Psychiatric Outpatients Christoph U. Correll, Benjamin G. Druss, Ilise Lombardo, Psychiatric Services	2010	108
Effects of high-dose ziprasidone and haloperidol on the QTc interval after intramuscular administration: A randomized, single-blind, parallel-group study in patients with schizophrenia or schizoaffective disorder Jeffrey Miceli, Thomas G. Tensfeldt, Thomas Shiovitz, Clinical Therapeutics PsychiatryPsychotic DisorderQtc IntervalPsychopharmacologySchizophrenia	2010	44
Effects of Oral Ziprasidone and Oral Haloperidol on QTc Interval in Patients with Schizophrenia or Schizoaffective Disorder Jeffrey Miceli, Thomas G. Tensfeldt, Thomas Shiovitz, Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy	2010	42
Examining the reliability and validity of the Clinical Assessment Interview for Negative Symptoms within the Management of Schizophrenia in Clinical Practice (MOSAIC) multisite national study Jack J. Blanchard, Kristen Bradshaw, Cristina P. Garcia, Schizophrenia Research PsychopathologyPsychiatric EvaluationPsychiatryPsychotic DisorderSchizophrenia	2017	42
Agitation in Alzheimer's disease: Novel outcome measures reflecting the International Psychogeriatric Association (IPA) agitation criteria Adélaïde De Mauléon, Zahinoor Ismail, Paul B. Rosenberg, Alzheimer s & Dementia	2021	31
The humanistic and economic burden of providing care for a patient with schizophrenia Csilla Csoboth, Edward A. Witt, Kathleen F. Villa, International Journal of Social Psychiatry	2015	30
Clinical Global Impression of Improvement (CGI-I) as a valid proxy measure for remission in schizophrenia: Analyses of ziprasidone clinical study data Prakash S. Masand, Cedric O’Gorman, Francine S. Mandel Schizophrenia Research PsychiatryPsychotic DisorderValid Proxy MeasureSchizophreniaNeuropsychiatry	2010	24
The Management of Schizophrenia in Clinical Practice (MOSAIC) Registry: A focus on patients, caregivers, illness severity, functional status, disease burden and healthcare utilization Henry A. Nasrallah, Philip D. Harvey, Daniel E. Casey, Schizophrenia Research NursingPsychosocial RehabilitationPsychiatryIllness SeveritySchizophrenia	2015	21

Page 1